Sami Corlan's questions to Allogene Therapeutics Inc (ALLO) leadership • Q3 2024
Question
Brooke on for Sami Corlan asked about the level of physician interest in the ALPHA3 trial and what specific aspects of using cema-cel in the first-line setting—such as community use, affordability, or time to treat—are considered most valuable.
Answer
Dr. Zachary Roberts, EVP of R&D and CMO, described physician enthusiasm as 'extremely high,' comparable to the early days of Yescarta's development. He stated that physicians see value in all the mentioned aspects: the ability to use a novel MRD prognostic test, respond immediately with an off-the-shelf therapy, and crucially, provide access to CAR-T treatment in community settings that previously could not offer it.